MedImmune to Develop Vaccines for Flu
Posted on: Wednesday, 28 September 2005, 12:00 CDT
GAITHERSBURG, Md. - Drug-maker MedImmune Inc. said Wednesday it will work with federal researchers to develop a vaccine to be used against versions of the influenza virus that could cause wide outbreaks, including the avian flu.
After the news, shares of MedImmune rose 5 percent, up $1.56 to $33.14 in morning trading Wednesday on the Nasdaq Market.
MedImmune and the National Institute of Allergy and Infectious Diseases will test MedImmune's technique of using weakened live flu viruses to see if it is effective against strains that may lead to pandemics.
That includes the H5N1 avian influenza strain, a lethal form that has appeared in southeast Asia and jumps from birds to humans. Scientists fear it could mutate and spread rapidly from person to person, sparking a global pandemic.
MedImmune and NIAID researchers plan to alter a harmful protein in the H5N1 strain and create a version that could be used in a vaccine meant to help people develop immunity to the virus.
The technique is based on MedImmune's use of live attenuated viruses, weakened forms of flu virus that are squirted into a patient's nose. Traditional flu shots use killed flu viruses to develop immunity. MedImmune uses the live virus in its FluMist vaccine.
Source: Associated Press/AP Online
Related Articles
- Sanofi Pasteur Begins Shipments of Fluzone(R), Influenza Virus Vaccine for 2009-2010 Seasonal Influenza
- West Nile Virus Vaccine Under Development
- Novartis Begins Shipment to US of Fluvirin(R) Influenza Virus Vaccine With Three New Strains for the 2008-2009 Influenza Season
- Live H5N1 Avian Flu Virus Vaccines Show Protection in Animal Studies
- Hungary's Bird Flu Vaccine Developer to Get 8-Mln-Euro Loan
- Bird Flu Vaccine Developed in St. Pete to Be Tested
- Chiron Delivers FLUVIRIN(R) Influenza Virus Vaccine to U.S. Customers
- Sanofi Pasteur Donates 200,000 Doses of Fluzone(R), Influenza Virus Vaccine to Support Government's Hurricane Relief Efforts
- Chiron Will Not Supply BEGRIVAC(TM) Influenza Virus Vaccine to Non-U.S. Markets
- FDA On-Site Inspection of Chiron's FLUVIRIN(R) Influenza Virus Vaccine Facility Underway
User Comments (0)

RSS Feeds